AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to creating treatments for rare, chronic, and significant infectious diseases, announced its financial results for the fourth quarter and the full year ending December 31, 2023. The company highlighted its sturdy financial position, with cash, cash equivalents, and investments totaling $134.5 million as of the end of 2023.
Focusing on advancing its boron-based therapy pipeline, AN2 Therapeutics continues to see promising potential in epetraborole for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium Complex (TR-MAC). Despite a temporary pause in Phase 3 enrollment due to an ongoing analysis, the company is proceeding with dosing for patients already enrolled in its pivotal Phase 2/3 trial, known as EBO-301. This halt follows a reassessment of blinded aggregate data from the Phase 2 portion of the trial that indicated efficacy levels potentially lower than anticipated.
Epetraborole’s double-blind, placebo-controlled trial is designed to evaluate its efficacy in conjunction with a background regimen against a placebo plus background regimen in patients with TR-MAC lung disease. With Phase 2 patients having reached the six-month mark, AN2 Therapeutics is set to report topline results in the summer of 2024. Considering the baseline characteristics of the patient demographics, which show a group with complex comorbidities and a history of refractory responses to current treatments, the company aims to engage in discussions with the FDA regarding the trial’s future.
Eric Easom, Co-Founder, President, and CEO of AN2 Therapeutics, expressed optimism regarding the ongoing development of their innovative pipeline and the potential of epetraborole as a crucial therapy for NTM lung disease. The company is also excited about other promising boron therapy candidates in their pipeline, including a novel therapy for chronic Chagas disease in late preclinical development and an IV formulation of epetraborole for melioidosis.
Besides epetraborole, AN2 Therapeutics is expanding its portfolio with various research programs and a recent licensing agreement to develop a therapy for chronic Chagas disease, exhibiting their commitment to addressing unmet patient needs across a range of infectious diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
